Risk Factors, Incidence, and Prognosis of Thromboembolism in Cancer Patients Treated With Immune Checkpoint Inhibitors

In recent years, immune checkpoint inhibitors (ICIs) have become the standard treatment option for tumors. With the widespread application of ICIs, immune-related adverse events (irAEs) have gradually attracted the attention of researchers. Owing to the characteristics of ICIs, irAEs can affect each...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Xue-lin Zou, Wei-yong Chen, Guang-yan Zhang, Hua Ke, Qiu-hong Yang, Xiao-bo Li
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	immune checkpoint inhibitors (ICIs) incidence risk factors thromboembolism prognosis Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/6f643805f9cf4647b9fe532a3cf11118
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6f643805f9cf4647b9fe532a3cf11118
record_format	dspace
spelling	oai:doaj.org-article:6f643805f9cf4647b9fe532a3cf111182021-11-08T06:47:21ZRisk Factors, Incidence, and Prognosis of Thromboembolism in Cancer Patients Treated With Immune Checkpoint Inhibitors1663-981210.3389/fphar.2021.747075https://doaj.org/article/6f643805f9cf4647b9fe532a3cf111182021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fphar.2021.747075/fullhttps://doaj.org/toc/1663-9812In recent years, immune checkpoint inhibitors (ICIs) have become the standard treatment option for tumors. With the widespread application of ICIs, immune-related adverse events (irAEs) have gradually attracted the attention of researchers. Owing to the characteristics of ICIs, irAEs can affect each organ of the human body. Thromboembolism is uncommon in cancer patients receiving ICIs, but it may affect their survival. Most thromboembolic events do not cause serious effects after early prediction and treatment, but life-threatening toxic reactions are also observed. This condition should not be ignored because of vague and atypical symptoms, which make early diagnosis more challenging. This article focuses on the high-risk factors, underlying mechanisms, incidence, and prognosis of thromboembolism in patients using ICIs and briefly describes the intervention and treatment measures. This information would allow patients to effectively manage the side effects of thromboembolism during Immune checkpoint inhibitors treatment, ensuring the efficacy of ICIs and reducing mortality.Xue-lin ZouWei-yong ChenGuang-yan ZhangHua KeQiu-hong YangXiao-bo LiFrontiers Media S.A.articleimmune checkpoint inhibitors (ICIs)incidencerisk factorsthromboembolismprognosisTherapeutics. PharmacologyRM1-950ENFrontiers in Pharmacology, Vol 12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	immune checkpoint inhibitors (ICIs) incidence risk factors thromboembolism prognosis Therapeutics. Pharmacology RM1-950
spellingShingle	immune checkpoint inhibitors (ICIs) incidence risk factors thromboembolism prognosis Therapeutics. Pharmacology RM1-950 Xue-lin Zou Wei-yong Chen Guang-yan Zhang Hua Ke Qiu-hong Yang Xiao-bo Li Risk Factors, Incidence, and Prognosis of Thromboembolism in Cancer Patients Treated With Immune Checkpoint Inhibitors
description	In recent years, immune checkpoint inhibitors (ICIs) have become the standard treatment option for tumors. With the widespread application of ICIs, immune-related adverse events (irAEs) have gradually attracted the attention of researchers. Owing to the characteristics of ICIs, irAEs can affect each organ of the human body. Thromboembolism is uncommon in cancer patients receiving ICIs, but it may affect their survival. Most thromboembolic events do not cause serious effects after early prediction and treatment, but life-threatening toxic reactions are also observed. This condition should not be ignored because of vague and atypical symptoms, which make early diagnosis more challenging. This article focuses on the high-risk factors, underlying mechanisms, incidence, and prognosis of thromboembolism in patients using ICIs and briefly describes the intervention and treatment measures. This information would allow patients to effectively manage the side effects of thromboembolism during Immune checkpoint inhibitors treatment, ensuring the efficacy of ICIs and reducing mortality.
format	article
author	Xue-lin Zou Wei-yong Chen Guang-yan Zhang Hua Ke Qiu-hong Yang Xiao-bo Li
author_facet	Xue-lin Zou Wei-yong Chen Guang-yan Zhang Hua Ke Qiu-hong Yang Xiao-bo Li
author_sort	Xue-lin Zou
title	Risk Factors, Incidence, and Prognosis of Thromboembolism in Cancer Patients Treated With Immune Checkpoint Inhibitors
title_short	Risk Factors, Incidence, and Prognosis of Thromboembolism in Cancer Patients Treated With Immune Checkpoint Inhibitors
title_full	Risk Factors, Incidence, and Prognosis of Thromboembolism in Cancer Patients Treated With Immune Checkpoint Inhibitors
title_fullStr	Risk Factors, Incidence, and Prognosis of Thromboembolism in Cancer Patients Treated With Immune Checkpoint Inhibitors
title_full_unstemmed	Risk Factors, Incidence, and Prognosis of Thromboembolism in Cancer Patients Treated With Immune Checkpoint Inhibitors
title_sort	risk factors, incidence, and prognosis of thromboembolism in cancer patients treated with immune checkpoint inhibitors
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/6f643805f9cf4647b9fe532a3cf11118
work_keys_str_mv	AT xuelinzou riskfactorsincidenceandprognosisofthromboembolismincancerpatientstreatedwithimmunecheckpointinhibitors AT weiyongchen riskfactorsincidenceandprognosisofthromboembolismincancerpatientstreatedwithimmunecheckpointinhibitors AT guangyanzhang riskfactorsincidenceandprognosisofthromboembolismincancerpatientstreatedwithimmunecheckpointinhibitors AT huake riskfactorsincidenceandprognosisofthromboembolismincancerpatientstreatedwithimmunecheckpointinhibitors AT qiuhongyang riskfactorsincidenceandprognosisofthromboembolismincancerpatientstreatedwithimmunecheckpointinhibitors AT xiaoboli riskfactorsincidenceandprognosisofthromboembolismincancerpatientstreatedwithimmunecheckpointinhibitors
_version_	1718442919195574272

Risk Factors, Incidence, and Prognosis of Thromboembolism in Cancer Patients Treated With Immune Checkpoint Inhibitors

Ejemplares similares